Forte Biosciences, Inc., founded in the United States, is a biopharmaceutical company dedicated to developing treatments for autoimmune diseases. The company's core mission is to address large unmet medical needs in conditions such as Graft-versus-Host Disease (GvHD), Vitiligo, and Alopecia Areata. Forte's lead product, FB-, is a proprietary molecule designed to treat these autoimmune and autoimmune-related diseases, with an initial focus on GvHD, a serious complication often associated with allogeneic hematopoietic stem cell transplants.

Notable affiliated individuals and investors in Forte Biosciences include experienced professionals from the biotech and pharmaceutical industries, though specific names are not provided. The company has made significant strides in its field, particularly with the development of its lead product aimed at treating multiple autoimmune conditions. Forte Biosciences' impact lies in its potential to provide effective treatments for patients with severe autoimmune diseases, addressing critical gaps in current medical therapies.